Bulk Pharmaceutical API Sources for sodium iodide i-123

Bulk Pharmaceutical API Sources for sodium iodide i-123

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		11954386
BenchChem		B1247706
THE BioTek		bt-1580549
J&H Chemical Co.,ltd		JH295517
RR Scientific		R215943

Sodium Iodide I-123 Bulk API Sources

Last updated: February 19, 2026

This analysis identifies key suppliers of bulk Sodium Iodide I-123 (NaI-123) active pharmaceutical ingredient (API) and relevant market considerations. The global supply chain for radiopharmaceuticals is characterized by specialized manufacturing, stringent regulatory oversight, and limited production capacity, impacting availability and pricing.

Who Are the Primary Manufacturers of Bulk NaI-123 API?

The production of bulk NaI-123 API is concentrated among a small number of global entities possessing the specialized infrastructure and regulatory approvals for radionuclide production and purification. These entities typically operate nuclear reactors or accelerators to produce Iodine-123, which is then processed into the pharmaceutical-grade API.

Key manufacturers include:

• Nordion Inc. (a Sotera Health company): Nordion is a significant global supplier of medical isotopes, including I-123. They utilize nuclear reactors for production and have a well-established distribution network for radiopharmaceuticals and related APIs. Their operations are subject to strict Canadian Nuclear Safety Commission (CNSC) and U.S. Food and Drug Administration (FDA) regulations.

• Curium: Curium is a major player in the radiopharmaceutical market, producing a range of diagnostic and therapeutic agents. They are involved in the production and distribution of I-123-based radiopharmaceuticals, implying involvement in the bulk API supply chain, though their specific I-123 API manufacturing sites are proprietary. Curium operates globally and adheres to various international regulatory standards, including those from the European Medicines Agency (EMA) and the FDA.

• ITM Isotopen Technologien München AG: ITM is a German company focused on the development and production of targeted radiopharmaceuticals. They employ cyclotron-based production of I-123. Their focus on novel radiopharmaceutical applications suggests a robust understanding of the I-123 API market. ITM is regulated by German and EU health authorities.

• Other Potential Suppliers: While less publicly prominent for bulk API supply, other entities may contribute to regional or specialized I-123 isotope production, potentially including national laboratories or research institutions with reactor facilities capable of producing I-123, which could then be processed into API. For instance, facilities in Japan (e.g., Japan Atomic Energy Agency) or Belgium may contribute to global isotope supply.

The production of I-123 is primarily achieved through two methods:

1. Direct Neutron Irradiation of Tellurium-122 (¹²²Te): This is the most common method, where a ¹²²Te target is irradiated in a nuclear reactor to produce ¹²³Te, which then decays to ¹²³I. ¹²²Te (n, γ) ¹²³Te → ¹²³I + β⁻ + νe

2. Accelerator Production via the ¹²⁷I(p, 5n)¹²³Xe → ¹²³I pathway: This method uses a proton beam to bombard Iodine-127, producing Xenon-123, which decays to Iodine-123. This method is less common for bulk API but is utilized for specific applications.

The purification process to achieve pharmaceutical-grade NaI-123 API involves the removal of impurities such as other iodine isotopes (e.g., I-131, I-135), tellurium isotopes, and other radio/stable nuclides. This purification is critical for safety and efficacy.

What Are the Regulatory Requirements for Bulk NaI-123 API?

The regulatory landscape for bulk radiopharmaceutical APIs like NaI-123 is exceptionally stringent due to the radioactive nature of the substance and its direct administration to patients. Manufacturers must comply with Good Manufacturing Practices (GMP) specific to radioactive materials.

Key regulatory aspects include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines as defined by regulatory bodies such as the FDA (21 CFR Parts 210 and 211, with specific considerations for radioactive drugs), EMA, and national health authorities. For radiopharmaceuticals, GMP includes enhanced controls for radiation safety, handling, containment, and quality control of short-lived isotopes.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, stability, and packaging of the API. Drug product manufacturers can reference these DMFs in their marketing authorization applications. For NaI-123, DMFs would include specifics on the radionuclide production route, purification techniques, impurity profiles, and radiochemical purity assays.

• Radioactive Material Licenses: Production facilities must hold specific licenses from nuclear regulatory bodies (e.g., CNSC in Canada, NRC in the U.S.) to possess, use, and produce radioactive materials. These licenses dictate facility design, security, waste management, and personnel training.

• Quality Control and Testing: Rigorous testing is required for each batch of bulk NaI-123 API. This includes:

  • Radiochemical Purity: Assays to determine the percentage of the desired radioactive isotope in its intended chemical form. This is crucial as unbound radioiodide can lead to unwanted biodistribution.
  • Radionuclidic Purity: Tests to identify and quantify the presence of other radioactive isotopes.
  • Chemical Purity: Standard pharmaceutical purity tests to identify and quantify non-radioactive impurities.
  • Sterility and Endotoxins: Although the API itself may not be terminally sterilized if it is processed into a sterile drug product, controls are in place to minimize microbial contamination.
  • pH and Osmolality: Relevant for API stability and subsequent formulation.

• Stability and Shelf-Life: I-123 has a relatively short half-life (13.2 hours), necessitating careful consideration of production scheduling, shipping, and storage to ensure the API maintains its quality and potency until it is formulated and administered. Stability studies are critical for determining the appropriate re-test period or expiry date for the API.

• International Harmonization: While national regulations are paramount, international guidelines from bodies like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) influence GMP standards and quality control testing protocols, promoting consistency across regions.

What Are the Market Dynamics and Supply Chain Challenges for NaI-123 API?

The market for bulk NaI-123 API is characterized by niche demand, high production costs, and significant logistical complexities.

Key market dynamics and challenges include:

• Limited Production Capacity: The number of nuclear reactors or accelerators capable of producing I-123 is limited globally. Disruptions at any of these facilities, whether due to scheduled maintenance, unforeseen technical issues, or geopolitical factors, can significantly impact global supply.

• Short Half-Life and Logistical Demands: The 13.2-hour half-life of I-123 dictates that production, purification, shipping, and formulation must occur within a narrow timeframe. This requires highly efficient, integrated supply chains and often necessitates production facilities located strategically to serve major radiopharmaceutical formulation centers. Cold chain logistics are also critical to maintain the integrity of the API during transit.

• High Cost of Production: Nuclear reactor or accelerator operation, specialized target materials, complex purification processes, stringent quality control, and regulatory compliance all contribute to a high cost of goods for I-123 API.

• Dependence on Specific Isotope Production: The primary production route via neutron irradiation of ¹²²Te means that the supply is directly tied to the availability of this specific target material and the operational status of reactors capable of producing neutrons of the required flux.

• Demand for Diagnostic Imaging: NaI-123 is predominantly used in diagnostic imaging modalities such as Single Photon Emission Computed Tomography (SPECT). Its use in SPECT myocardial perfusion imaging, thyroid imaging, and brain imaging drives demand. The development of new SPECT tracers or increased utilization of existing ones directly influences the demand for NaI-123 API.

• Competition and Alternative Isotopes: While I-123 is established, advancements in PET imaging and the development of new PET tracers (e.g., using F-18 or Ga-68) can shift diagnostic preferences and impact the market share of SPECT agents. However, I-123 remains a cost-effective and widely available option for many SPECT applications.

• Geopolitical and Economic Factors: Global events, trade policies, and currency fluctuations can affect the cost and availability of raw materials, as well as shipping and distribution costs, thereby influencing the final price of NaI-123 API.

• Consolidation in the Radiopharmaceutical Industry: Mergers and acquisitions among radiopharmaceutical companies and isotope suppliers can lead to changes in market structure, potentially affecting pricing and supply dynamics for bulk APIs.

The supply chain for NaI-123 API can be visualized as:

• Isotope Production: Nuclear reactors or accelerators produce the radioactive precursor (e.g., ¹²³Te or ¹²³Xe).
• Chemical Conversion & Purification: Raw radioiodine is converted to sodium iodide and purified to pharmaceutical grade.
• Bulk API Manufacturing: Final purification, dispensing, and packaging of NaI-123 API into shielded containers.
• Distribution: Licensed radiopharmaceutical distributors transport the API under strict temperature and security controls to drug product manufacturers.
• Drug Product Formulation: Radiopharmaceutical manufacturers use the bulk API to formulate radiolabeled diagnostic or therapeutic agents.
• Patient Administration: Formulated radiopharmaceuticals are administered to patients.

Each step is subject to rigorous oversight and quality assurance.

What Are the Key Quality Attributes for Bulk NaI-123 API?

The critical quality attributes (CQAs) for bulk NaI-123 API are dictated by its intended pharmaceutical use and the need to ensure patient safety and diagnostic accuracy.

Key CQAs include:

• Identity: The API must be unequivocally identified as Sodium Iodide I-123. This is typically confirmed through gamma-ray spectroscopy, measuring the characteristic emissions of I-123.

• Radiochemical Purity: This is a paramount CQA. For NaI-123 intended for formulation into radiopharmaceuticals, the free iodide percentage must be exceptionally low. For example, in a sodium iodide solution, unbound I-123 would contribute to thyroid uptake in procedures not intended for the thyroid. Typical specifications are >95% or >98% radiochemical purity.

• Radionuclidic Purity: The presence of other radioactive impurities, particularly those with longer half-lives or different emission energies, can interfere with imaging or pose additional radiation risks. For I-123, key impurities to control include ¹²⁴I (half-life 4.2 days), ¹²⁵I (half-life 59.4 days), ¹²⁶I (half-life 13.0 days), ¹³¹I (half-life 8.0 days), and ¹³⁵I (half-life 6.5 hours). Regulatory bodies set maximum allowable limits for these and other radionuclidic contaminants.

• Chemical Purity: Non-radioactive impurities, such as residual tellurium from the production process or other inorganic salts, must be controlled to meet pharmacopeial standards (e.g., USP, Ph. Eur.) for pharmaceutical ingredients.

• Specific Activity: The amount of radioactivity per unit mass of the chemical compound. For I-123, specific activity is important for dose calculations and can influence formulation strategies. High specific activity is generally desired to minimize the mass of carrier material administered.

• pH: The pH of a solution of NaI-123 API is important for stability and compatibility with subsequent formulation steps. Specifications typically fall within a physiological range, e.g., 4.0-7.0.

• Sterility and Endotoxins: While bulk API may not be terminally sterilized, stringent controls are in place to minimize microbial contamination. If the API is to be directly formulated into an injectable product without further sterilization, it must meet sterility and low endotoxin requirements. Often, formulation processes include sterilization steps like sterile filtration.

• Appearance: The physical form of the API (e.g., clear, colorless solution) and freedom from particulate matter are assessed.

• Radionuclidic Identity: Confirmation of the principal gamma-ray energy of I-123 (159 keV, with minor emissions at 177 keV, 428 keV, and 529 keV).

These CQAs are verified through a battery of analytical tests performed on each batch before its release for use in drug product manufacturing.

Key Takeaways

• The global supply of bulk Sodium Iodide I-123 (NaI-123) API is concentrated among a few specialized manufacturers, including Nordion, Curium, and ITM.
• Production relies on nuclear reactors or accelerators, with neutron irradiation of ¹²²Te being the dominant method.
• Regulatory compliance, particularly GMP for radioactive materials, is extensive, involving Drug Master Files and specific radioactive material licenses.
• The short half-life of I-123 (13.2 hours) imposes significant logistical demands on production, distribution, and formulation, requiring highly integrated and efficient supply chains.
• Key quality attributes for NaI-123 API include high radiochemical and radionuclidic purity, accurate identity, and controlled chemical impurities, essential for safe and effective diagnostic imaging.
• Market dynamics are shaped by limited production capacity, high production costs, the logistical challenges of short half-life isotopes, and the demand driven by SPECT imaging applications.

FAQs

1. What is the typical lead time for ordering bulk NaI-123 API, considering its short half-life? Lead times are typically very short, ranging from a few days to one week. Due to the 13.2-hour half-life, API is usually manufactured and shipped on demand, requiring close coordination between the API supplier, distributor, and drug product manufacturer to align production schedules with formulation needs.

2. How are supply chain disruptions at major I-123 production facilities managed by drug product manufacturers? Manufacturers often secure supply from multiple approved vendors if feasible. They also maintain close communication with suppliers to monitor production schedules and potential risks. Contingency planning may involve adjusting production schedules for formulated drugs or, in severe cases, temporarily halting production of certain I-123-based radiopharmaceuticals.

3. Are there geographical limitations on the supply of NaI-123 API due to transport regulations for radioactive materials? Yes, the transport of radioactive materials is subject to strict national and international regulations (e.g., IAEA regulations). These regulations dictate packaging, labeling, documentation, and permissible transport routes. This can lead to longer transit times and higher shipping costs for international shipments, influencing the strategic placement of manufacturing and formulation facilities.

4. What are the primary analytical methods used to confirm the radionuclidic purity of NaI-123 API? Gamma-ray spectroscopy is the primary method. High-purity germanium (HPGe) detectors are used for precise energy and intensity measurements of gamma rays emitted by the sample. This allows for the identification and quantification of various iodine isotopes (e.g., ¹²⁴I, ¹³¹I) and other potential radionuclidic impurities by comparing their characteristic gamma-ray spectra to known standards.

5. Does the USP or Ph. Eur. have specific monographs for bulk Sodium Iodide I-123 API, and what do they typically specify? Yes, both the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) have monographs for "Sodium Iodide I-123 Injection," which implicitly define the quality attributes of the API used in its preparation. These monographs specify requirements for identity, assay (radioactivity concentration), radiochemical purity, radionuclidic purity (limits for specific impurities like ¹²⁴I, ¹³¹I), pH, and bacterial endotoxins. While a separate monograph for bulk NaI-123 API might not exist in isolation, the requirements for the finished injectable product dictate the critical quality attributes for the API.

---

Citations

[1] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA website] (Specific CFR references are typically cited directly within the text or via internal company standards referencing these regulations.) [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from [EMA website] (Specific directives and guidelines on GMP for radiopharmaceuticals are referenced within.) [3] International Atomic Energy Agency. (n.d.). Regulations for the Safe Transport of Radioactive Material. Retrieved from [IAEA website] [4] Nordion Inc. (n.d.). Products and Services. Retrieved from [Nordion website] [5] Curium. (n.d.). Our Products. Retrieved from [Curium website] [6] ITM Isotopen Technologien München AG. (n.d.). Products. Retrieved from [ITM website] [7] United States Pharmacopeia. (n.d.). USP <821> Biological and Radiopharmaceutical Drugs; Radiopharmaceuticals. Retrieved from [USP website] (Specific monograph details are accessed via subscription.) [8] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). European Pharmacopoeia. Retrieved from [EDQM website] (Specific monograph details are accessed via subscription.)